SV2011003816A - Amidofenoxiindazoles utiles como inhibidores de c-met - Google Patents

Amidofenoxiindazoles utiles como inhibidores de c-met

Info

Publication number
SV2011003816A
SV2011003816A SV2011003816A SV2011003816A SV2011003816A SV 2011003816 A SV2011003816 A SV 2011003816A SV 2011003816 A SV2011003816 A SV 2011003816A SV 2011003816 A SV2011003816 A SV 2011003816A SV 2011003816 A SV2011003816 A SV 2011003816A
Authority
SV
El Salvador
Prior art keywords
useful
amidophenoxyindazols
met inhibitors
inhibitors
met
Prior art date
Application number
SV2011003816A
Other languages
English (en)
Inventor
Tiechao Li
Mark Andrew Pobanz
Chuan Shih
Wei Jennifer Yang
Boyu Zhong
Zhipei Wu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV2011003816A publication Critical patent/SV2011003816A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE AMIDOFENOXIINDAZOL ÚTILES EN EL TRATAMIENTO DE CÁNCER
SV2011003816A 2008-07-24 2011-01-21 Amidofenoxiindazoles utiles como inhibidores de c-met SV2011003816A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8329408P 2008-07-24 2008-07-24
US8508208P 2008-07-31 2008-07-31
US10865908P 2008-10-27 2008-10-27

Publications (1)

Publication Number Publication Date
SV2011003816A true SV2011003816A (es) 2011-03-17

Family

ID=41010247

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2011003816A SV2011003816A (es) 2008-07-24 2011-01-21 Amidofenoxiindazoles utiles como inhibidores de c-met

Country Status (36)

Country Link
US (2) US8030302B2 (es)
EP (1) EP2310382B1 (es)
JP (1) JP5414794B2 (es)
KR (1) KR101334456B1 (es)
CN (1) CN102105462B (es)
AR (1) AR074632A1 (es)
AT (1) ATE546444T1 (es)
AU (1) AU2009274256B2 (es)
BR (1) BRPI0916286B8 (es)
CA (1) CA2731773C (es)
CL (1) CL2011000134A1 (es)
CO (1) CO6351737A2 (es)
CR (1) CR20110046A (es)
CY (1) CY1112595T1 (es)
DK (1) DK2310382T3 (es)
DO (1) DOP2011000009A (es)
EA (1) EA018385B1 (es)
EC (1) ECSP11010778A (es)
ES (1) ES2379587T3 (es)
HK (1) HK1155172A1 (es)
HR (1) HRP20120202T1 (es)
IL (1) IL210490A (es)
JO (1) JO2788B1 (es)
MA (1) MA32594B1 (es)
MX (1) MX2011000925A (es)
MY (1) MY163852A (es)
NZ (1) NZ590013A (es)
PE (1) PE20110150A1 (es)
PL (1) PL2310382T3 (es)
PT (1) PT2310382E (es)
RS (1) RS52261B (es)
SI (1) SI2310382T1 (es)
SV (1) SV2011003816A (es)
TW (1) TWI365185B (es)
WO (1) WO2010011538A1 (es)
ZA (1) ZA201100219B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
CA2820709C (en) 2011-02-28 2016-02-16 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
US8962623B2 (en) * 2011-03-04 2015-02-24 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
JP6129956B2 (ja) * 2012-05-09 2017-05-17 イーライ リリー アンド カンパニー 抗ｃ−Ｍｅｔ抗体
US9790206B2 (en) * 2013-02-27 2017-10-17 Array Biopharma Inc. Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
CN104140393B (zh) * 2013-12-10 2016-09-21 郑州泰基鸿诺医药股份有限公司 一种芳环/芳杂环叔丁醇酯类化合物的制备方法
US20150299219A1 (en) 2014-04-22 2015-10-22 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
TW201716085A (zh) * 2015-08-12 2017-05-16 應克隆公司 癌症之組合療法
CN109069632A (zh) * 2016-04-15 2018-12-21 伊莱利利公司 用于治疗结直肠癌的雷莫芦单抗和merestinib的组合
AU2017273147A1 (en) 2016-06-02 2019-01-03 Immunocore Limited Dosing regimen for GP100-specific TCR - anti-CD3 SCFV fusion protein
EP3490676A1 (en) * 2016-07-29 2019-06-05 Eli Lilly and Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
CN108069938A (zh) * 2016-11-15 2018-05-25 中国药科大学 2,4-二取代吡啶类化合物及其制备方法和应用
US20210283249A1 (en) 2016-11-16 2021-09-16 Eli Lilly And Company Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
CN109982700A (zh) * 2016-11-16 2019-07-05 伊莱利利公司 具有外显子14跳跃突变或外显子14跳跃表型的癌症的治疗
CN107311983A (zh) * 2017-07-06 2017-11-03 北京万全德众医药生物技术有限公司 吲哚类小分子c‑met抑制剂
CN107382968A (zh) * 2017-07-06 2017-11-24 北京万全德众医药生物技术有限公司 一种吲哚类c‑Met抑制剂的制备方法
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
EP3480201A1 (en) 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
EP3719012B1 (en) 2017-11-24 2024-03-06 Medshine Discovery Inc. N-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophenyl]-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxamide derivatives as c-met/axl inhibitors for the treatment of tumors
CN110041316B (zh) * 2018-01-17 2022-04-19 药捷安康(南京)科技股份有限公司 Tam家族激酶/和csf1r激酶抑制剂及其用途
AU2019237715B2 (en) 2018-03-08 2021-01-28 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
BR112021003447A2 (pt) * 2018-08-24 2021-05-18 Nanjing Transthera Biosciences Co., Ltd. inibidor derivado de quinolina inovador
CN112739691B (zh) * 2018-09-03 2023-05-23 泰励生物科技（上海）有限公司 用作抗癌药的trk抑制剂
JP2022554042A (ja) 2019-09-06 2022-12-28 ウェルマーカー・バイオ・カンパニー・リミテッド バイオマーカー型治療用組成物
KR20220170766A (ko) * 2021-06-22 2022-12-30 주식회사 엘지화학 단백질 키나아제 억제제로서의 신규한 화합물
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US5484681A (en) * 1994-10-31 1996-01-16 Xerox Corporation Conductive composite particles and processes for the preparation thereof
IL114149A0 (en) * 1995-06-14 1995-10-31 Yeda Res & Dev Modified avidin and streptavidin molecules and use thereof
US5747577A (en) * 1995-12-27 1998-05-05 Xerox Corporation Conductive particles containing carbon black and processes for the preparation thereof
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
EP1400808B1 (en) * 2001-05-18 2006-06-28 Srl, Inc. Immunoassay method
US6956084B2 (en) * 2001-10-04 2005-10-18 Bridgestone Corporation Nano-particle preparation and applications
JP2004067703A (ja) * 2002-04-24 2004-03-04 Japan Science & Technology Corp 架橋ポリマー、微粒子および製造方法
US7192780B2 (en) * 2002-10-23 2007-03-20 Evident Technologies Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals
US7737153B2 (en) 2002-10-28 2010-06-15 Bayer Schering Pharma Aktiengesellschaft Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
CA2532711C (en) * 2003-07-17 2013-07-23 Dynal Biotech Asa Coating of porous, surface functionalized, superparamagnetic crystal-containing polymer particles with polyisocyanate/diol and/or epoxide monomers
US7163998B2 (en) * 2003-09-09 2007-01-16 Eastman Kodak Company Stabilized polymer beads and method of preparation
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EA015754B1 (ru) 2005-12-21 2011-12-30 Янссен Фармацевтика, Н.В. Триазолопиридазины в качестве модуляторов тирозинкиназы
EP2001880A2 (en) * 2006-03-07 2008-12-17 Array Biopharma, Inc. Heterobicyclic pyrazole compounds and methods of use
WO2008003099A1 (en) * 2006-06-29 2008-01-03 Invitrogen, Dynal As Particles containing multi- block polymers
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
PT2084162E (pt) 2006-10-23 2012-10-09 Sgx Pharmaceuticals Inc Triazoles bicíclicos como moduladores de proteína quinase
US8076521B2 (en) 2007-06-27 2011-12-13 Arkema Inc. Process for the manufacture of hydrofluoroolefins

Also Published As

Publication number Publication date
BRPI0916286B1 (pt) 2019-10-08
MX2011000925A (es) 2011-03-21
CN102105462B (zh) 2014-07-23
CR20110046A (es) 2011-04-27
CA2731773C (en) 2013-03-12
KR101334456B1 (ko) 2013-11-29
CO6351737A2 (es) 2011-12-20
MY163852A (en) 2017-10-31
HK1155172A1 (en) 2012-05-11
MA32594B1 (fr) 2011-09-01
HRP20120202T1 (hr) 2012-03-31
US20100022529A1 (en) 2010-01-28
PT2310382E (pt) 2012-04-11
PE20110150A1 (es) 2011-03-07
TWI365185B (en) 2012-06-01
DK2310382T3 (da) 2012-03-26
AR074632A1 (es) 2011-02-02
DOP2011000009A (es) 2011-03-31
WO2010011538A1 (en) 2010-01-28
ZA201100219B (en) 2012-06-27
ES2379587T3 (es) 2012-04-27
IL210490A0 (en) 2011-03-31
ATE546444T1 (de) 2012-03-15
BRPI0916286B8 (pt) 2021-05-25
SI2310382T1 (sl) 2012-04-30
NZ590013A (en) 2012-06-29
CY1112595T1 (el) 2016-02-10
ECSP11010778A (es) 2011-02-28
AU2009274256B2 (en) 2013-07-11
US8030302B2 (en) 2011-10-04
JP5414794B2 (ja) 2014-02-12
PL2310382T3 (pl) 2012-07-31
CL2011000134A1 (es) 2011-07-08
USRE43878E1 (en) 2012-12-25
RS52261B (en) 2012-10-31
EA201170252A1 (ru) 2011-06-30
EP2310382A1 (en) 2011-04-20
EP2310382B1 (en) 2012-02-22
CN102105462A (zh) 2011-06-22
CA2731773A1 (en) 2010-01-28
AU2009274256A1 (en) 2010-01-28
EA018385B1 (ru) 2013-07-30
KR20110022691A (ko) 2011-03-07
IL210490A (en) 2013-06-27
JP2011529054A (ja) 2011-12-01
TW201006817A (en) 2010-02-16
JO2788B1 (en) 2014-03-15

Similar Documents

Publication Publication Date Title
SV2011003816A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
CR20110580A (es) Compuestos vinil indazolilo
BRPI0916375A2 (pt) compostos orgânicos como inibidores de smo
UY31432A1 (es) Compuestos de diarilhidantoina
CR20120659A (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer
CR20120641A (es) Compuestos macrocìclicos como inhibidores de quinasa trk
ME01665B (me) Analozi buprenorfina
MA32938B1 (fr) Composes organiques
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
EP2273852A4 (en) ORGANIC ELECTROLUMINESCENTS LIGHTING SOURCE
BRPI0917017A2 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
BRPI1010795A2 (pt) compostos antivirais
HN2007015177A (es) Derivados de triazolopirazina
BRPI0819606A2 (pt) amino triazóis como inobidores de pi3k
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
GT200800075S (es) Diseño de embudo
GT201200084A (es) Antitransparente que reduce/elimina la decoloración amarilla en las prendas de vestir
BRPI0912234A2 (pt) derivados de salinosporamida como inibidores de proteassomas
BRPI0912475A8 (pt) compostos como inibidores de quinase
GT200800018S (es) Diseño de motoneta
BRPI1010874A2 (pt) composição para o tratamento de câncer de próstata
BRPI0922884A2 (pt) compostos para tratamento de câncer
DE112010001827A5 (de) Betriebsschaltung fur Leuchtdioden
BRPI0910691A2 (pt) compostos e composições como inibidores de itpkb
GT201400169A (es) Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2

Legal Events

Date Code Title Description
FG Grant